Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HRH1 | P35367 | 2/20 | 0.58 |
| ▸ | HTR1B | P28222 | 2/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31528226 | 1.00 | ALDH1A1 (0.67) | ALDH1A1HPGDHTTSMN1; SMN2HRH1 | |
| SCHEMBL11729416 | 0.95 | ALDH1A1 (0.65) | ALDH1A1HPGDHTTSMN1; SMN2HRH1 | |
| SCHEMBL19328405 | 0.93 | ALDH1A1 (0.62) | ALDH1A1HPGDHTTSMN1; SMN2HRH1 | |
| SCHEMBL4888000 | 0.91 | ALDH1A1 (0.69) | ALDH1A1HPGDHTTSMN1; SMN2HRH1 | |
| Hydrochloric Acid SCHEMBL6561435 | 0.90 | ALDH1A1 (0.67) | ALDH1A1HPGDHTTSMN1; SMN2HRH1 | |
| SCHEMBL11669697 | 0.83 | ALDH1A1 (0.62) | ALDH1A1HPGDHTTSMN1; SMN2HTR1B | |
| SCHEMBL5805320 | 0.83 | ALDH1A1 (0.87) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL8372730 | 0.83 | ALDH1A1 (0.87) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL3446273 | 0.83 | HTR1B (0.57) | ALDH1A1HRH1HTR1BKDM4EHTR7 | |
| SCHEMBL19342150 | 0.82 | ALDH1A1 (0.66) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | claimed |
| EP-2245132-A1 | ENCAPSULATED BENEFIT AGENT | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2010-11-03 | — | — | EP | claimed |
| WO-2009103576-A1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC (GB) | 2009-08-27 | — | — | WO | claimed |
| US-12281119-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEIGENE, LTD. (KY) | 2025-04-22 | — | — | US | disclosed |
| EP-3921320-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | disclosed |
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2022-04-21 | — | — | US | disclosed |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3539962-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2970330-B1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| US-4127606-A | Substituted sulfonamides having antiinflammatory activity | E. R. SQUIBB & SONS, INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4122255-A | Substituted amides and sulfonamides containing a heterocyclic group having antiinflammatory activity | E. R. SQUIBB & SONS, INC. (US) | 1978-10-24 | — | — | US | disclosed |
| US-4098789-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-07-04 | — | — | US | disclosed |
| US-4064120-A | 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity | E. R. SQUIBB & SONS, INC. (US) | 1977-12-20 | — | — | US | disclosed |
| US-4064125-A | Substituted amides having antiinflammatory activity | E. R. SQUIBB AND SONS, INC. (US) | 1977-12-20 | — | — | US | disclosed |
| US-4053471-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-10-11 | — | — | US | disclosed |
| US-4053514-A | ANTIDEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1977-10-11 | — | — | US | disclosed |
| US-4038274-A | ANTIDEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1977-07-26 | — | — | US | disclosed |
| US-3969527-A | INDENO(1,2-C)PYRAZOLE | E. R. SQUIBB & SONS, INC. (US) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | ALDH1A1 2163/4885HPGD 2388/4885HTT 1423/4885 |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | ALDH1A1 2163/4885HPGD 2388/4885HTT 1423/4885 |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | ALDH1A1 2163/4885HPGD 2388/4885HTT 1423/4885 |
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR3 | ALDH1A1 1611/4885HPGD 4530/4885HTT 4372/4885 |
| US-12281119-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR1, TLR3 | ALDH1A1 1611/4885HPGD 4530/4885HTT 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.